Deep Longitudinal Proteomics Profiling Reveals Biological Pathways Responding to GRF6019 in Two AD Clinical Trials | Zendy

Benoit Lehallier | Zendy; Tibor Nánási | Zendy; Jonas Hannestad | Zendy; Steven P. Braithwaite | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Deep Longitudinal Proteomics Profiling Reveals Biological Pathways Responding to GRF6019 in Two AD Clinical Trials

Author(s) -

Benoit Lehallier,

Tibor Nánási,

Jonas Hannestad,

Steven P. Braithwaite

Publication year - 2021

Publication title -

innovation in aging

Language(s) - English

Resource type - Journals

ISSN - 2399-5300

DOI - 10.1093/geroni/igab046.016

Subject(s) - proteomics , clinical trial , computational biology , bioinformatics , biological pathway , biology , tolerability , neuroscience , medicine , pharmacology , adverse effect , genetics , gene expression , gene

Blood has been widely investigated to discover biomarkers and gain insights into the biology of aging and age-related diseases. Its protein composition provides insights into complex biological processes, as proteins are often direct regulators of cellular pathways. In clinical trials, selected proteins have been used as primary and secondary endpoints, but recent methodological developments allow the measurement of thousands of proteins with very high sensitivity and specificity. In two phase 2 clinical trials testing the safety, tolerability, and feasibility of infusions of the plasma fraction GRF6019 in Alzheimer's disease (AD), we measured more than 7000 proteins in plasma over the course of the clinical trials. Differential trajectories analysis revealed groups of proteins and pathways that were responding to GRF6019. Several pathways were relevant to the biology of aging and AD and our study suggests that deep proteomics profiling can inform on specific biological processes responding to treatment in clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research